No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Junshi Biosciences' Teplizumab Injection Included in China's 2025 Drug Insurance Catalog; Shares Up 6%
Express News | Shanghai Junshi Biosciences - Toripalimab Injection Were Successfully Included in Category B of National Drug List for Basic Medical Insurance
Junshi bio (688180.SH): Tuoyi's new indications included in the national medical insurance directory.
On November 28, Junshi Bio (688180.SH) announced that its product Toripalimab Injection (trade name: Tuoyi, product code: JS001) has successfully added 4 new indications to the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2024)" (referred to as the "National Medical Insurance List"). The new version of the National Medical Insurance List will be officially implemented starting from January 1, 2025. As of the date of this announcement, Tuoyi has all 10 indications approved in mainland China included in the National Medical Insurance List, making it the only drug in the National Medical Insurance List used for melanoma.
Dr. Reddy's Launches Toripalimab Immuno-oncology Drug in India
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%
No Data
